NANALYSIS SCIENTIFIC CORP (NSCI.CA) Stock Fundamental Analysis
TSX-V:NSCI - CA63000Y1034 - Common Stock
0.22 CAD
+0.01 (+4.76%)
Taking everything into account, NSCI scores 4 out of 10 in our fundamental rating. NSCI was compared to 16 industry peers in the Health Care Equipment & Supplies industry. While NSCI seems to be doing ok healthwise, there are quite some concerns on its profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on NSCI.
1. Profitability
1.1 Basic Checks
NSCI had negative earnings in the past year.
In the past year NSCI had a positive cash flow from operations.
NSCI had negative earnings in each of the past 5 years.
NSCI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
NSCI has a Return On Assets of -32.18%. This is amongst the best in the industry. NSCI outperforms 87.50% of its industry peers.
NSCI's Return On Equity of -87.12% is amongst the best of the industry. NSCI outperforms 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.18% | ||
| ROE | -87.12% | ||
| ROIC | N/A |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NSCI has a worse Gross Margin (29.18%) than 62.50% of its industry peers.
In the last couple of years the Gross Margin of NSCI has declined.
NSCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.18% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
2. Health
2.1 Basic Checks
NSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NSCI has been increased compared to 1 year ago.
NSCI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NSCI is higher compared to a year ago.
2.2 Solvency
NSCI has an Altman-Z score of -0.34. This is a bad value and indicates that NSCI is not financially healthy and even has some risk of bankruptcy.
NSCI has a better Altman-Z score (-0.34) than 81.25% of its industry peers.
NSCI has a debt to FCF ratio of 6.14. This is a slightly negative value and a sign of low solvency as NSCI would need 6.14 years to pay back of all of its debts.
NSCI has a better Debt to FCF ratio (6.14) than 100.00% of its industry peers.
NSCI has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
NSCI has a Debt to Equity ratio of 0.50. This is in the better half of the industry: NSCI outperforms 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.14 | ||
| Altman-Z | -0.34 |
ROIC/WACCN/A
WACC6.11%
2.3 Liquidity
A Current Ratio of 0.86 indicates that NSCI may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.86, NSCI is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
NSCI has a Quick Ratio of 0.86. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.59, NSCI perfoms like the industry average, outperforming 56.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.59 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 41.55% over the past year.
NSCI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.37%.
Measured over the past years, NSCI shows a very strong growth in Revenue. The Revenue has been growing by 40.32% on average per year.
EPS 1Y (TTM)41.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)13.37%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-5.09%
3.2 Future
NSCI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.33% yearly.
Based on estimates for the next years, NSCI will show a small growth in Revenue. The Revenue will grow by 5.66% on average per year.
EPS Next Y81.82%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y34.33%
Revenue Next Year-0.13%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.66%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NSCI. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 5.45 indicates a rather cheap valuation of NSCI.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NSCI indicates a rather cheap valuation: NSCI is cheaper than 100.00% of the companies listed in the same industry.
NSCI is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.63, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.45 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NSCI is valued cheaply inside the industry as 93.75% of the companies are valued more expensively.
100.00% of the companies in the same industry are more expensive than NSCI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.68 | ||
| EV/EBITDA | 24.71 |
4.3 Compensation for Growth
NSCI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NSCI's earnings are expected to grow with 45.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.14%
EPS Next 3Y45.9%
5. Dividend
5.1 Amount
NSCI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:NSCI (9/4/2025, 7:00:00 PM)
0.22
+0.01 (+4.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners3.93%
Ins Owner ChangeN/A
Market Cap25.26M
Analysts80
Price Target0.84 (281.82%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-98.02%
Min EPS beat(2)-98.02%
Max EPS beat(2)-98.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.47%
Min Revenue beat(2)-7.14%
Max Revenue beat(2)8.09%
Revenue beat(4)3
Avg Revenue beat(4)17.69%
Min Revenue beat(4)-7.14%
Max Revenue beat(4)53.52%
Revenue beat(8)6
Avg Revenue beat(8)17.17%
Revenue beat(12)7
Avg Revenue beat(12)3.21%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.45 | ||
| P/S | 0.56 | ||
| P/FCF | 9.68 | ||
| P/OCF | 5.64 | ||
| P/B | 1.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 24.71 |
EPS(TTM)-0.11
EYN/A
EPS(NY)0.04
Fwd EY18.36%
FCF(TTM)0.02
FCFY10.33%
OCF(TTM)0.04
OCFY17.73%
SpS0.39
BVpS0.12
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.18% | ||
| ROE | -87.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.18% | ||
| FCFM | 5.81% |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
F-Score6
Asset Turnover1.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.14 | ||
| Debt/EBITDA | 4.43 | ||
| Cap/Depr | 42.5% | ||
| Cap/Sales | 4.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 280.93% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.59 | ||
| Altman-Z | -0.34 |
F-Score6
WACC6.11%
ROIC/WACCN/A
Cap/Depr(3y)97.82%
Cap/Depr(5y)114.88%
Cap/Sales(3y)16.41%
Cap/Sales(5y)20.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y81.82%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y34.33%
Revenue 1Y (TTM)13.37%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-5.09%
Revenue Next Year-0.13%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.66%
EBIT growth 1Y81.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year253.78%
EBIT Next 3Y72.2%
EBIT Next 5Y52.43%
FCF growth 1Y114.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y139.78%
OCF growth 3YN/A
OCF growth 5Y33.1%